Yifan Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yifan Yang has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Zoltan Arany
Cardiovascular Institute Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
5 shared publications - Benjamin L. Prosser
Department of Physiology, Pennsylvania Muscle Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia (B.L.P.).
2 shared publications Jeffrey Brandimarto
Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
2 shared publications- Michael P. Morley
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
2 shared publications - Nora Yucel
Cardiovascular Institute (Y.Y., E.W.B., S.L.K., J.B., L. Li, L. Lai, J.G., N.Y., S.S., D.M.E., K.C.B., K.B.M., Z.A., J.J.E.), Perelman School of Medicine, University of Pennsylvania, Philadelphia
2 shared publications Sunhye Jeong
Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
2 shared publications
Latest Publications
- 12 November 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (20) , 1648-1651
Sex-Specific Effects of MTSS1 Downregulation on Dilated Cardiomyopathy
- 12 November 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (20) , 1648-1651
Sex-Specific Effects of MTSS1 Downregulation on Dilated Cardiomyopathy
- Open Access
- 15 December 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (24)
Endothelial lipid droplets suppress eNOS to link high fat consumption to blood pressure elevation
Metabolic syndrome, today affecting more than 20% of the US population, is a group of 5 conditions that often coexist and that strongly predispose to cardiovascular disease. How these conditions are linked mechanistically remains unclear, especially two of these: obesity and elevated blood pressure. Here, we show that high fat consumption in mice leads to the accumulation of lipid droplets in endothelial cells throughout the organism and that lipid droplet accumulation in endothelium suppresses endothelial nitric oxide synthase (eNOS), reduces NO production, elevates blood pressure, and accelerates atherosclerosis. Mechanistically, the accumulation of lipid droplets destabilizes eNOS mRNA and activates an endothelial inflammatory signaling cascade that suppresses eNOS and NO production. Pharmacological prevention of lipid droplet formation reverses the suppression of NO production in cell culture and in vivo and blunts blood pressure elevation in response to a high-fat diet. These results highlight lipid droplets as a critical and unappreciated component of endothelial cell biology, explain how lipids increase blood pressure acutely, and provide a mechanistic account for the epidemiological link between obesity and elevated blood pressure.
- 15 December 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (24)
Open AccessEndothelial lipid droplets suppress eNOS to link high fat consumption to blood pressure elevation
Metabolic syndrome, today affecting more than 20% of the US population, is a group of 5 conditions that often coexist and that strongly predispose to cardiovascular disease. How these conditions are linked mechanistically remains unclear, especially two of these: obesity and elevated blood pressure. Here, we show that high fat consumption in mice leads to the accumulation of lipid droplets in endothelial cells throughout the organism and that lipid droplet accumulation in endothelium suppresses endothelial nitric oxide synthase (eNOS), reduces NO production, elevates blood pressure, and accelerates atherosclerosis. Mechanistically, the accumulation of lipid droplets destabilizes eNOS mRNA and activates an endothelial inflammatory signaling cascade that suppresses eNOS and NO production. Pharmacological prevention of lipid droplet formation reverses the suppression of NO production in cell culture and in vivo and blunts blood pressure elevation in response to a high-fat diet. These results highlight lipid droplets as a critical and unappreciated component of endothelial cell biology, explain how lipids increase blood pressure acutely, and provide a mechanistic account for the epidemiological link between obesity and elevated blood pressure.
- Top Cited Papers
- 15 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 376 (6590) , 264-+
Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) remain without effective therapies. The mechanistic target of rapamycin complex 1 (mTORC1) pathway is a potential therapeutic target, but conflicting interpretations have been proposed for how mTORC1 controls lipid homeostasis. We show that selective inhibition of mTORC1 signaling in mice, through deletion of the RagC/D guanosine triphosphatase–activating protein folliculin (FLCN), promotes activation of transcription factor E3 (TFE3) in the liver without affecting other mTORC1 targets and protects against NAFLD and NASH. Disease protection is mediated by TFE3, which both induces lipid consumption and suppresses anabolic lipogenesis. TFE3 inhibits lipogenesis by suppressing proteolytic processing and activation of sterol regulatory element–binding protein-1c (SREBP-1c) and by interacting with SREBP-1c on chromatin. Our data reconcile previously conflicting studies and identify selective inhibition of mTORC1 as a potential approach to treat NASH and NAFLD.
- 15 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 376 (6590) , 264-+
Top Cited PapersInhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) remain without effective therapies. The mechanistic target of rapamycin complex 1 (mTORC1) pathway is a potential therapeutic target, but conflicting interpretations have been proposed for how mTORC1 controls lipid homeostasis. We show that selective inhibition of mTORC1 signaling in mice, through deletion of the RagC/D guanosine triphosphatase–activating protein folliculin (FLCN), promotes activation of transcription factor E3 (TFE3) in the liver without affecting other mTORC1 targets and protects against NAFLD and NASH. Disease protection is mediated by TFE3, which both induces lipid consumption and suppresses anabolic lipogenesis. TFE3 inhibits lipogenesis by suppressing proteolytic processing and activation of sterol regulatory element–binding protein-1c (SREBP-1c) and by interacting with SREBP-1c on chromatin. Our data reconcile previously conflicting studies and identify selective inhibition of mTORC1 as a potential approach to treat NASH and NAFLD.
- 3 November 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (618) , eabd7287
Truncated titin proteins in dilated cardiomyopathy
Truncating mutations in TTN result in both truncated titin proteins and reduced full-length titin in patient hearts.
- 3 November 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (618) , eabd7287
Truncated titin proteins in dilated cardiomyopathy
Truncating mutations in TTN result in both truncated titin proteins and reduced full-length titin in patient hearts.
- 3 September 2021
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 129 (Suppl_1)
Abstract P322: Ror2: A Novel Regulator Of Cardiomyocyte Structure And Target Of Right Ventricular Failure
Introduction: We recently identified the fetal noncanonical WNT receptor ROR2 as being re-expressed in human right ventricular failure (RVF), but the myocardial role of ROR2 remains poorly described. Hypothesis: We assessed if ROR2 expression influences cardiomyocyte structure or contributes to RVF pathogenesis. Methods: ROR2 gain- and loss-of-function (ROR2GOF and ROR2LOF) NRVMs were generated using adenoviral-delivered ROR2 cDNA or shRNA and cultured on nanopatterned substrates. NRVM structure was assessed by confocal microscopy (minimum n=3 replicates, >30 cells/condition). NRVM gene expression was characterized by RNAseq. The impact of ROR2 on RV structure and function was assessed using AAV9-mediated cardiac ROR2 delivery, in 4-week old C57BL/6 mice (vs GFP), and echocardiography and hemodynamics (n= 8, 50% male). Results: ROR2GOF disrupts non-sarcomeric and sarcomeric NRVM structure, exhibiting smaller (500 vs. 711 μm2, p = 7.4x10-23) and rounder (aspect ratio 2.1 vs. 3.1, p=1.9x10-16) shape and fragmented sarcomeres (Figure). Whereas, ROR2LOF NRVMs demonstrate a striking peripheralization of α-actinin and β-catenin. Gene-set enrichment analyses of ROR2GOF NRVMs reveal upregulation of cytokinesis, mitosis, microtubule regulation, and insulin like growth factor receptor signaling. By 4 weeks after induction of ROR2GOFin vivo, mice exhibit biventricular dilation and systolic dysfunction (TAPSE 0.85 vs 1.2 mm, p = 2.1x10-5; right ventricular outflow dimension 2.0 vs 1.7 mm, p = 0.001, LV EDV 33.5 vs 28.6 μL, p = 0.05; LV ejection fraction 63% vs 69%, p = 0.015). RV diastolic function is reduced in ROR2GOF (E:e’ 21.8 vs 18.6, p = 0.004 and RV EDP 2.9 vs 1.0 mmHg, p = 0.06). Conclusions: ROR2GOF causes biventricular dilation, systolic and diastolic dysfunction in vivo. In vitro, ROR2GOF NRVMs exhibit an immaturity phenotype with maintenance of proliferation gene program. In contrast, ROR2LOF NRVMs form a tight monolayer with enhanced cell-cell borders. Download figure
- 3 September 2021
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 129 (Suppl_1)
Abstract P322: Ror2: A Novel Regulator Of Cardiomyocyte Structure And Target Of Right Ventricular Failure
Introduction: We recently identified the fetal noncanonical WNT receptor ROR2 as being re-expressed in human right ventricular failure (RVF), but the myocardial role of ROR2 remains poorly described. Hypothesis: We assessed if ROR2 expression influences cardiomyocyte structure or contributes to RVF pathogenesis. Methods: ROR2 gain- and loss-of-function (ROR2GOF and ROR2LOF) NRVMs were generated using adenoviral-delivered ROR2 cDNA or shRNA and cultured on nanopatterned substrates. NRVM structure was assessed by confocal microscopy (minimum n=3 replicates, >30 cells/condition). NRVM gene expression was characterized by RNAseq. The impact of ROR2 on RV structure and function was assessed using AAV9-mediated cardiac ROR2 delivery, in 4-week old C57BL/6 mice (vs GFP), and echocardiography and hemodynamics (n= 8, 50% male). Results: ROR2GOF disrupts non-sarcomeric and sarcomeric NRVM structure, exhibiting smaller (500 vs. 711 μm2, p = 7.4x10-23) and rounder (aspect ratio 2.1 vs. 3.1, p=1.9x10-16) shape and fragmented sarcomeres (Figure). Whereas, ROR2LOF NRVMs demonstrate a striking peripheralization of α-actinin and β-catenin. Gene-set enrichment analyses of ROR2GOF NRVMs reveal upregulation of cytokinesis, mitosis, microtubule regulation, and insulin like growth factor receptor signaling. By 4 weeks after induction of ROR2GOFin vivo, mice exhibit biventricular dilation and systolic dysfunction (TAPSE 0.85 vs 1.2 mm, p = 2.1x10-5; right ventricular outflow dimension 2.0 vs 1.7 mm, p = 0.001, LV EDV 33.5 vs 28.6 μL, p = 0.05; LV ejection fraction 63% vs 69%, p = 0.015). RV diastolic function is reduced in ROR2GOF (E:e’ 21.8 vs 18.6, p = 0.004 and RV EDP 2.9 vs 1.0 mmHg, p = 0.06). Conclusions: ROR2GOF causes biventricular dilation, systolic and diastolic dysfunction in vivo. In vitro, ROR2GOF NRVMs exhibit an immaturity phenotype with maintenance of proliferation gene program. In contrast, ROR2LOF NRVMs form a tight monolayer with enhanced cell-cell borders. Download figure
- Open Access
- 14 December 2020
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 9
Cardiac endothelial cells maintain open chromatin and expression of cardiomyocyte myofibrillar genes
Endothelial cells (ECs) are widely heterogenous depending on tissue and vascular localization. Jambusaria et al. recently demonstrated that ECs in various tissues surprisingly possess mRNA signatures of their underlying parenchyma. The mechanism underlying this observation remains unexplained, and could include mRNA contamination during cell isolation, in vivo mRNA paracrine transfer from parenchymal cells to ECs, or cell-autonomous expression of these mRNAs in ECs. Here, we use a combination of bulk RNASeq, single-cell RNASeq datasets, in situ mRNA hybridization, and most importantly ATAC-Seq of FACS-isolated nuclei, to show that cardiac ECs actively express cardiomyocyte myofibril (CMF) genes and have open chromatin at CMF gene promoters. These open chromatin sites are enriched for sites targeted by cardiac transcription factors, and closed upon expansion of ECs in culture. Together, these data demonstrate unambiguously that the expression of CMF genes in ECs is cell-autonomous, and not simply a result of technical contamination or paracrine transfers of mRNAs, and indicate that local cues in the heart in vivo unexpectedly maintain fully open chromatin in ECs at genes previously thought limited to cardiomyocytes.
- 14 December 2020
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 9
Open AccessCardiac endothelial cells maintain open chromatin and expression of cardiomyocyte myofibrillar genes
Endothelial cells (ECs) are widely heterogenous depending on tissue and vascular localization. Jambusaria et al. recently demonstrated that ECs in various tissues surprisingly possess mRNA signatures of their underlying parenchyma. The mechanism underlying this observation remains unexplained, and could include mRNA contamination during cell isolation, in vivo mRNA paracrine transfer from parenchymal cells to ECs, or cell-autonomous expression of these mRNAs in ECs. Here, we use a combination of bulk RNASeq, single-cell RNASeq datasets, in situ mRNA hybridization, and most importantly ATAC-Seq of FACS-isolated nuclei, to show that cardiac ECs actively express cardiomyocyte myofibril (CMF) genes and have open chromatin at CMF gene promoters. These open chromatin sites are enriched for sites targeted by cardiac transcription factors, and closed upon expansion of ECs in culture. Together, these data demonstrate unambiguously that the expression of CMF genes in ECs is cell-autonomous, and not simply a result of technical contamination or paracrine transfers of mRNAs, and indicate that local cues in the heart in vivo unexpectedly maintain fully open chromatin in ECs at genes previously thought limited to cardiomyocytes.
- Open Access
- 15 September 2020
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 84 (2) , 233-241
Systematic review and meta-analysis of the effectiveness and safety of hydroxychloroquine in treating COVID-19 patients
Background: Since COVID-19 outbreak, hydroxychloroquine (HCQ) has been tested for effective therapies, and the relevant researches have shown controversial results. Methods: Systematic review and meta-analysis were conducted after a thorough search of relevant studies from databases. Trials that have evaluated HCQ for COVID-19 treatment were recruited for statistical analysis with fixed- and random-effect models. Results: Nine trials involving 4112 patients were included in present meta-analysis. It was seen that HCQ-azithromycin (HCQ-AZI) combination regimen increased the mortality rate in COVID-19 (odds ratio [OR], 2.34; 95% confidence interval [CI], 1.63–3.36) patients; however, it also showed benefits associated with the viral clearance in patients (OR, 27.18; 95% CI, 1.29–574.32). HCQ-alone when used as a therapy in COVID-19 did not reveal significant changes in mortality rate, clinical progression, viral clearance, and cardiac QT prolongation. Subsequent subgroup analysis showed that HCQ treatment could decrease mortality rate and progression to severe illness in severely infected COVID-19 patients (OR, 0.27; 95% CI, 0.13–0.58). A lower risk of mortality rate was also noted in the stratified group of >14 days follow-up period (OR, 0.27; 95% CI, 0.13–0.58) compared to ≤14 days follow-up period group that conversely showed an increased mortality rate (OR, 2.09; 95% CI, 1.41–3.10). Conclusion: Our results indicated that HCQ-AZI combination treatment increased mortality rate in patients with COVID-19, but it also showed benefits associated with viral clearance in patients. HCQ-alone used for treatment has revealed benefits in decreasing the mortality rate among severely infected COVID-19 group and showed potential to be used for COVID-19 treatment in long-term follow-up period group. Accordingly, more rigorous, large-scale, and long follow-up period studies in patients with COVID-19 are needed.
- 15 September 2020
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 84 (2) , 233-241
Open AccessSystematic review and meta-analysis of the effectiveness and safety of hydroxychloroquine in treating COVID-19 patients
Background: Since COVID-19 outbreak, hydroxychloroquine (HCQ) has been tested for effective therapies, and the relevant researches have shown controversial results. Methods: Systematic review and meta-analysis were conducted after a thorough search of relevant studies from databases. Trials that have evaluated HCQ for COVID-19 treatment were recruited for statistical analysis with fixed- and random-effect models. Results: Nine trials involving 4112 patients were included in present meta-analysis. It was seen that HCQ-azithromycin (HCQ-AZI) combination regimen increased the mortality rate in COVID-19 (odds ratio [OR], 2.34; 95% confidence interval [CI], 1.63–3.36) patients; however, it also showed benefits associated with the viral clearance in patients (OR, 27.18; 95% CI, 1.29–574.32). HCQ-alone when used as a therapy in COVID-19 did not reveal significant changes in mortality rate, clinical progression, viral clearance, and cardiac QT prolongation. Subsequent subgroup analysis showed that HCQ treatment could decrease mortality rate and progression to severe illness in severely infected COVID-19 patients (OR, 0.27; 95% CI, 0.13–0.58). A lower risk of mortality rate was also noted in the stratified group of >14 days follow-up period (OR, 0.27; 95% CI, 0.13–0.58) compared to ≤14 days follow-up period group that conversely showed an increased mortality rate (OR, 2.09; 95% CI, 1.41–3.10). Conclusion: Our results indicated that HCQ-AZI combination treatment increased mortality rate in patients with COVID-19, but it also showed benefits associated with viral clearance in patients. HCQ-alone used for treatment has revealed benefits in decreasing the mortality rate among severely infected COVID-19 group and showed potential to be used for COVID-19 treatment in long-term follow-up period group. Accordingly, more rigorous, large-scale, and long follow-up period studies in patients with COVID-19 are needed.